End-of-day quote
Other stock markets
|
||
- USD | - |
2014 | Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug | RE |
2014 | Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback | RE |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Karen Rogers
PRN | Corporate Officer/Principal | - | - |
Sales & Marketing | - | - | |
Corporate Officer/Principal | - | 01/97/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 70 | 01/06/01 | |
Director/Board Member | 70 | 25/13/25 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 76,295,299 | 75,907,820 ( 99.49 %) | 0 | 99.49 % |
Company contact information
Cubist Pharmaceuticals LLC
155 Federal Street Suite 700
02110, Boston
+781-860-8660
http://www.cubist.comSector
1st Jan change | Capi. | |
---|---|---|
-3.35% | 88.91B | |
+4.08% | 41.25B | |
-15.09% | 31.99B | |
+51.46% | 24.73B | |
-15.13% | 15.54B | |
-8.63% | 12.05B | |
-40.39% | 12.07B | |
+6.22% | 8.84B | |
-5.15% | 8.3B |
- Stock Market
- Equities
- Stock
- Company Cubist Pharmaceuticals Inc